Replies to post #186783 on Biotech Values

[DewDiligence]

JNJ/GILD—FDA approves Prezcobix FDC (Prezista + Cobicstat):

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

GILD’s Cobicstat (a constituent of Stribild and Complera) is an alternative to ritonavir for boosting JNJ’s HIV protease inhibitor, Prezista.

JNJ will book sales of Prezcobix; the companies haven’t disclosed how much GILD will be paid for the Cobicstat component.

Note the parallel to FDA approval of BMY’s Evotaz (#msg-110386161).

p.s. Prezcobix would be a superb Scrabble word if it weren’t a brand name.